The rare case of double valve surgery in a patient with factor VII deficiency.
Friederike I SchoettlerAli Fatehi HassanabadMichael H ChiuAndre FerlandCorey AdamsPublished in: Perfusion (2023)
Performing cardiac surgery on patients with bleeding diatheses poses significant challenges since these patients are at an increased risk for complications secondary to excessive bleeding. Despite its rarity, patients with factor VII (FVII) deficiency may require invasive procedures such as cardiac surgery. However, we lack guidelines on their pre-, peri-, and post-operative management. As FVII deficiency is rare, it seems unlikely to design and learn from large clinical studies. Instead, we need to base our clinical decision-making on single reported cases and registry data. Herein, we present the rare case of a patient with FVII deficiency who underwent double valve surgery. Pre-operatively, activated recombinant FVII (rFVIIa) was administered to reduce the risk of bleeding. Nevertheless, the patient experienced major bleeding. This case highlights the significance of FVII deficiency in patients undergoing cardiac surgery and emphasizes the importance of adequate and appropriate transfusion of blood products for these patients.
Keyphrases
- cardiac surgery
- rare case
- end stage renal disease
- acute kidney injury
- atrial fibrillation
- ejection fraction
- patients undergoing
- newly diagnosed
- chronic kidney disease
- decision making
- mitral valve
- prognostic factors
- aortic valve
- peritoneal dialysis
- replacement therapy
- risk factors
- electronic health record
- machine learning
- patient reported outcomes
- weight gain
- big data
- acute coronary syndrome
- left ventricular
- sickle cell disease
- transcatheter aortic valve replacement
- weight loss